Alcohol Use Disorder

Can CBD Help With Alcohol Use Disorder? New Scientific Review Finds There's Something To It
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
Podcast: Clearmind's Non-Hallucinogenic Psychoactive Molecule Could Become A Solution For Addictive Behaviors
Awakn Life Sciences Submits CTA For Phase III Alcohol Use Disorder Clinical Trial
Psilocybin Therapy Trials: Gambling Addiction Study, Opioid Pain & Alcohol Addiction Trials
Awakn Life Sciences Sells London Clinics Business, Hopes To Divest Norwegian Unit Next

Alcohol Use Disorder Recent News

Awakn To Focus On R&D Of Addiction Therapies, Moves Away From Ketamine Treatment For Alcoholism
Psychedelics biotech Awakn Life Sciences Corp. (OTCQB: AWKNF) is set to exit ketamine healthcare services to focus solely on research and development of therapeutics to treat addiction and licensing of its intellectual property (IP.)
Psilocybin Therapy: Potential For Treating Alcoholism Examined In APA Publication
The peer-reviewed journal Psychology of Addictive Behaviors published by the American Psychological Association (APA) released a new analysis by Fluence, NYU and
MEAI Compound's First Clinical Trial In US, Clearmind Enters NASDAQ Compliance Period
Clearmind Medicine Inc. (NASDAQ: CMND), an Israel-based biotech company advancing the clinical stage for an MEAI-based compound targeting Alcohol Use Disorder (AUD,) has selected Yale School of Medicine’s Psychiatry Dept. as the first U.S. site for its Phase 1/2a trial on proprietary CMND-100.
EXCLUSIVE: Clearmind Medicine Secures Approval To Launch Clinical Trial For Alcohol Addiction Treatment
Clearmind Medicine Inc.
Next-Gen Israeli Psychedelics Company Gears Up For Trial Targeting Alcohol Addiction
Alcohol Use Disorder (AUD) is one of the top-targeted health issues by biopharma companies. In the case of Clearmind Medicine (NASDAQ: CMND), the Israel-based company is going at it through its MEAI-based proprietary drug candidate, CMND-100.
Awakn's Q4 2023 And Annual Financials, +500% YoY Revenue Increase Following Network Expansion
The UK-based psychedelics biotech company Awakn Life Sciences Corp. (OTCQB: AWKNF) reported on its financial results and business highlights for the three and twelve months ended Jan. 31, 2023.  
UK-Based Approach To Alcohol Addiction: 5-MeO-DMT Candidate Moves To Phase 2 Clinical Stage
Clinical-stage private biotech company Beckley Psytech Ltd has initiated a Phase 2a clinical study on its synthetic formulation of 5-MeO-DMT for the treatment of Alcohol Use Disorder (AUD) and will soon begin patient enrollment. 
A Drug That Mimics Alcohol Buzz Is Bound For Human Trials: Here's What's Next
Israeli biotech Clearmind Medicine Inc. (NASDAQ: CMND) has submitted an Investigational New Drug (IND) application with the FDA towards approval to commence its first-in-human Phase 1/2a clinical trial with MEAI-based CMND-100 in patients diagnosed with Alcohol Use Disorder (AUD). 
Shark Tank's Kevin Harrington Will Provide Strategic Guidance To Major Psychedelics Company
Psychedelics biopharma company FSD Pharma Inc. (NASDAQ: HUGE)’s advisory board has a new member: the iconic entrepreneur and inventor of the infomercial Kevin Harrington.
Awakn's First Licensing Partnership Deal In Europe Involves Chain Of Portuguese Clinics
Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.  
Psychedelics For Alcohol Use Disorder: Awakn Opens European Clinic, FSD Launches R&D Program
Awakn Opens Fourth European Clinic, Norway Takes Center Stage
Clinical Site In Alberta Begins Study Of Psychedelic-Assisted Treatment For Alcohol Use Disorder
Calgary-based SABI Mind is the first clinical site to receive approval from the Health Research Ethics Board of Alberta (HREBA) to launch a trial assessing psilocybin-assisted psychotherapy for the treatment of Alcohol Use Disorder (AUD).
Awakn's Ketamine Treatment For Alcohol Use Disorder Awarded UK's Fast-Track Status
Awakn Life Sciences Corp. (OTCQB: AWKNF), a biotech company developing therapeutics to treat addiction with a near-term focus on Alcohol Use Disorder (AUD), has been granted an Innovation Passport for its proprietary Ketamine-Assisted Therapy (KAT) to treat severe AUD.
Recreational Cannabis Legalization Correlated With Decrease In Alcohol Use Disorder, New Study Finds
A new study published in Psychological Medicine shows evidence that legalizing cannabis does not increase substance use disorders or use of other illicit drugs and therefore is not considered a gateway drug.
EXCLUSIVE: Next-Generation Psychedelics, MEAI - What And When
(Part three of a four-part series) See previous parts of the series: Next-Generation Psychedelics: The Case Of MEAI And Its Potential To Treat Addiction
Psychiatry And Business Collaborate: European Psychedelics Trial Tackles Alcohol Addiction
Clinical-stage natural psychedelics developer Filament Health (OTCQB: FLHLF) and the Psychiatric Center Copenhagen’s collaborative clinical trial has been approved by the Danish Medicines Agency and is set to commence this February. 
These Are The 11 Biggest Psychedelics News And Trends You May Have Missed Last Year
What a year for psychedelics!
Europe To Have Expanded Access To Psychedelic-Assisted Therapy With New Norway Clinic
Psychedelics biotech Awakn Life Sciences Corp.
Clearmind Gears Up For Clinical Trial To Test Drug That Treats Alcohol Addiction
Israeli psychedelics biotech Clearmind Medicine Inc. (NASDAQ: CMND) is commencing the production of its proprietary drug candidate based on the MEAI molecule.
A Leading Ketamine Treatment Clinic For Alcoholism Is Expanding: Here's The Latest
A psychedelics R&D biotech company, known for providing novel treatments for addictions, is opening a new ketamine clinic. 
EXCLUSIVE: New Partnership Brings Leading Psychedelic Protocol For Alcoholism Treatment To NYC
NYC-based clinics brand Nushama has partnered with Awakn Life Sciences (OTCQB: AWKNF), a clinical-stage psychedelics biotech company to bring
Can Ketamine Treat Alcohol Addiction? In-Clinic Therapy Vs. Retreats
(Part four of a four-part series - Read part three)
Can Ketamine Treat Alcohol Addiction? The Awakn Approach
(Part three of a four-part series)